AHA today urged Congress and the administration to take immediate action to rein in the rising cost of drugs, including passing the Creating and Restoring Equal Access to Equivalent Samples Act and H.R. 4392. “Spending on pharmaceuticals has increased dramatically over the past several years, and the primary driver is higher prices,” AHA Executive Vice President Tom Nickels told the House Energy and Commerce Health Subcommittee at a hearing examining how the drug supply chain affects pharmaceutical costs, access and delivery. The CREATES Act would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief, while H.R. 4392 would prevent the Centers for Medicare & Medicaid Services from reducing Medicare payments for hospital outpatient drugs under the 340B drug savings program by nearly 30% effective Jan. 1. “The 340B program permits safety-net hospitals that care for communities with a high number of low-income and uninsured patients to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive service,” Nickels told the committee.

Related News Articles

Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
Rep. Doris Matsui, D-Calif., and Sen. Peter Welch, D-Vt., today introduced the 340B Patients Act, AHA-supported legislation that would codify 340B providers'…
Headline
The AHA July 16 filed an amicus brief in the U.S. District Court for the District of Colorado in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
The U.S. District Court for the Eastern District of Missouri July 11 granted a motion by the state to dismiss claims by AbbVie that the state’s 340B contract…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…